Dr. Reddy’s, U.K. Firm Join For Self-Injectable Drug Sales
This article was originally published in PharmAsia News
Dr. Reddy's Laboratories of India has signed a contract with U.K.-based The Medical House to develop, license and supply drugs from India. The Medical House, a drug-delivery specialist, owns an auto injector device technology, which is to be customized and combined with an unnamed Dr. Reddy's drug to create a self-injectable product to reach the market within the next two years. The pact covers the United States, European and Canadian markets, but gives Dr. Reddy's an option to extend it to the rest of the world after the initial five years. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.